Leukemia and Lymphoma
Leukemia and lymphoma research concentrates on these hematologic malignancies, seeking improved therapies and patient outcomes. Recent developments involve targeted therapies and immunotherapies, offering new hope for treatment. Minimal residual disease monitoring helps assess treatment effectiveness. Additionally, CAR-T cell therapy exhibits promise in treating both leukemia and lymphoma. This field aims to enhance treatment precision and minimize side effects while advancing the understanding of disease mechanisms, ultimately improving the prognosis for individuals with these blood cancers.
- New therapies for leukemia and lymphoma.
- Minimal residual disease monitoring.
- CAR-T cell therapy in hematologic malignancies.
Related Conference of Leukemia and Lymphoma
Leukemia and Lymphoma Conference Speakers
Recommended Sessions
- Bleeding Disorders in Women
- Digital Health and Artificial Intelligence (AI) in Hematology
- Hematologic Gene Editing and Gene Therapies
- Hematology and Stem Cell Research
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Sickle Cell Disease
- Hemophilia Management and Research
- Hemostasis and Thrombosis
- Immunotherapy and Hematology
- Leukemia and Lymphoma
- Medicine in Hematology
- Molecular Hematology
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure
- Next-Generation Diagnostics and Imaging
- Novel Therapies for Blood Cancers
- Pediatric Hematology
- Platelet Disorders
- Sickle Cell Disease (SCD)
- Thalassemia Management
- Transfusion Medicine and Blood Banking
Related Journals
Are you interested in
- Advances in Hematologic Malignancies - Blood Disorders 2025 (Italy)
- Advances in Hemostasis and Thrombosis - Blood Disorders 2025 (Italy)
- Blood Disorders and the Immune System - Blood Disorders 2025 (Italy)
- Blood Disorders Diagnosis & Treatment - HEMATOLOGY 2025 (Spain)
- Blood Disorders in Aging Populations - Blood Disorders 2025 (Italy)
- Blood Transfusion - HEMATOLOGY 2025 (Spain)
- Case reports of Hematology - HEMATOLOGY 2025 (Spain)
- CellTherapy - HEMATOLOGY 2025 (Spain)
- COVID-19 and Hematology - HEMATOLOGY 2025 (Spain)
- Cutting-Edge Research in Blood Disorders - Blood Disorders 2025 (Italy)
- Disorders of Vascular Bleeding - HEMATOLOGY 2025 (Spain)
- Future Trends in Hematology: Artificial Intelligence and Big Data - Blood Disorders 2025 (Italy)
- Gene Therapy and Genetic Engineering in Hematology - Blood Disorders 2025 (Italy)
- Hematologic Toxicities and Side Effects of Cancer Therapy - Blood Disorders 2025 (Italy)
- Hematology - HEMATOLOGY 2025 (Spain)
- Hematology in Global Health: Addressing Disparities - Blood Disorders 2025 (Italy)
- Hematology Oncology - HEMATOLOGY 2025 (Spain)
- Immunohematology - HEMATOLOGY 2025 (Spain)
- Immunotherapy and Cellular Therapies in Hematology - Blood Disorders 2025 (Italy)
- Innovations in Red Blood Cell Disorders - Blood Disorders 2025 (Italy)
- Leukaemia and Lymphoma - HEMATOLOGY 2025 (Spain)
- Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation - HEMATOLOGY 2025 (Spain)
- New Drug Development in Hematology - HEMATOLOGY 2025 (Spain)
- Novel Diagnostic Techniques and Biomarkers in Hematology - Blood Disorders 2025 (Italy)
- Patient Blood Management - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology: Challenges and Innovations - Blood Disorders 2025 (Italy)
- Stem Cell Research - HEMATOLOGY 2025 (Spain)
- Stem Cell Transplantation and Regenerative Medicine - Blood Disorders 2025 (Italy)
- Thalassemia - HEMATOLOGY 2025 (Spain)
- Therapeutic Apheresis - HEMATOLOGY 2025 (Spain)
- Thrombosis and Coagulation - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine: Advances and Challenge - Blood Disorders 2025 (Italy)
- Transfusion Transmissible Infections - HEMATOLOGY 2025 (Spain)